This month featured ESMO updates, breast cancer trial news, social media strategies for oncologists, and mastectomy body ...

Researchers assessed preoperative lesion area as a predictor of final defect size in periocular basosquamous carcinoma cases.

In patients with extensive-stage small cell lung cancer, adding tarlatamab to durvalumab maintenance therapy significantly ...

Updated findings from the OptimUM trials support the use of darovasertib plus crizotinib in the treatment of patients with ...

Perioperative apalutamide plus ADT and surgery lowered risk of recurrence or death by 62% in high-risk localized or locally advanced prostate cancer.

Pembrolizumab continues to demonstrate a disease-free and overall survival benefit for patients with clear cell renal ...

Combining the novel, highly selective HDAC inhibitor HBI-8000 with nivolumab significantly improves PFS in unresectable ...

Combining adjuvant ribociclib with an NSAI improves long-term survival in HR-positive, HER2-negative early breast cancer over ...

Sanjay Juneja, MD, a triple board-certified hematologist and medical oncologist known as @TheOncDoc, translates oncology fundamentals.

Niraparib plus dostarlimab with definitive cisplatin plus radiotherapy improves some outcomes in patients with locally ...

In patients with muscle-invasive bladder cancer (MIBC), treatment with neoadjuvant durvalumab and enfortumab vedotin, with or ...

Nivolumab-ipilimumab prolongs OS compared to nivolumab alone or chemo in MSI-H or dMMR, unresectable or metastatic colorectal ...